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Abstract
Introduction: Parvovirus B19 (B19V) is the infectious cause of exanthema infectio-
sum. In Europe around 40% of pregnant women are susceptible to infection. Having 
small children at home is the main risk factor for contracting an infection during preg-
nancy. The association between B19V-infection and perinatal death is not yet settled. 
The aims of the study were to estimate the association between maternal parvovirus 
B19 infection in pregnancy and perinatal death, and to assess the significance of a 
positive B19V PCR in pregnancy.
Material and methods: The study population consists of women included in the 
Norwegian Mother and Child Cohort Study, a prospective population-based preg-
nancy cohort of nearly 100 000 women. Blood samples were obtained during weeks 
17-18 in pregnancy (M1), at birth, and in umbilical cord blood. Within participants in 
the pregnancy cohort, 138 cases of perinatal death and 1350 controls with live-born 
children were included in a nested case-control study. Samples were analyzed with 
B19V serology and B19V PCR according to a predefined test algorithm. For cases, 
medical records and laboratory results from hospitals were combined with the results 
of B19V serology and PCR. The reported causes of perinatal death were categorized 
using the classification system: Causes Of Death and Associated Conditions (CODAC).
Results: The B19V seroconversion rates were 9.8% for cases and 6.8% for control 
mothers. The odds ratio for maternal B19V infection in cases compared with controls 
was 1.28 (95% CI 0.35-4.70), adjusted for age, parity, body mass index and tobacco 
use. B19V-PCR-positive samples were detected at weeks 17-18 of gestation in both 
cases and controls. The proportion of positive samples was similar in cases and con-
trols, 24% and 28.2%, respectively. Mothers with PCR-positive M1 samples trans-
mitted B19V vertically in 9.1% of cases and in 11.9% of the controls. Of all perinatal 
deaths, 53% were attributed to placental pathology or unknown causes.
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1  | INTRODUC TION
Parvovirus B19 (B19V) is the infectious cause of exanthema 
infectiosum, a common disease in childhood.1 In pregnant 
women, more than 50% of B19V infections are asymptomatic. 
B19V is transmitted through respiratory droplets and occurs 
endemically worldwide with epidemic periods every 3-5 years. 
Seroconversion rates rise during epidemics. Having small chil-
dren at home is the main risk factor for infection.2 In Norway, 
as in many other countries, around 40% of women of fertile age 
are susceptible to infection.3,4 Pregnant women may vertically 
transmit the virus to the fetus in 1/3 of cases and fetal infection 
occurs in most cases within 12 weeks after maternal infection.5,6 
Maternal infection during the first 20 weeks of gestation has 
been associated with fetal death in 9%-11% and fetal hydrops 
in 3%-4% of pregnancies.5,7 The association between B19V in-
fection and perinatal death is not yet settled.8-11 A combination 
of serological methods and PCR analysis is recommended when 
investigating a possible B19V infection.12-14 As low-level viremia 
may persist after infection, the interpretation of B19V DNA de-
tection in pregnant women is unclear.15,16 Case-control studies 
are useful in estimating the association between B19V infections 
and disease.
Perinatal death rates vary between low- and high-income coun-
tries, and the distributions of causes differ. Globally, unexplained 
stillbirth is the most frequent category, constituting over 30% of 
all cases. There is a need to understand the consequences of B19V 
infection later in pregnancy. Virus may or may not cross the pla-
centa barrier, but infection of the placenta trophoblasts without the 
fetus being infected can still affect fetal development. P-antigen, 
also called globoside, is the receptor for B19V and is present on the 
trophoblasts’ cell surface. Although not permissive for B19V repli-
cation, it can infect and express cytotoxic NS1 proteins, which stim-
ulate apoptosis of the cell and may cause placental insufficiency or 
infarction.17,18 A classification system for fetal death is required for 
comparison of data between studies. In the present study, we have 
used the Causes Of Death and Associated Conditions (CODAC) sys-
tem to categorize cases.19
The aims of this study were (1) to estimate the odds ratio (OR) 
for maternal infection with B19V in mothers with and without peri-
natal death of a child, nested within a population-based pregnancy 
cohort and (2) to estimate the prevalence and significance of B19V 
PCR positivity in pregnancy.
2  | MATERIAL AND METHODS
The study population consists of women included in the Norwegian 
Mother and Child Cohort Study (MoBa)—a prospective population-
based pregnancy cohort conducted by the Norwegian Institute of 
Public Health.20,21 Participants were recruited from all over Norway 
from 1999 to 2008. The cohort includes 95 200 mothers, 114 500 
children and 75 200 fathers. Blood samples were obtained from moth-
ers during weeks 17-18 in pregnancy (M1) and at birth (M2). Umbilical 
cord blood from the child (C) was also collected.22 A total of 1350 con-
trols with available plasma samples and questionnaire data were ran-
domly selected and included (see Supplementary material, Table S1). 
One control later withdrew from the study and was excluded, leaving 
1349 controls eligible for analysis. Of the 1349 controls, 1 control had 
only the M1 and C samples, and another control had only the M1 and 
M2 samples. The rest had complete sets of plasma samples.
Within the cohort, 150 women were identified and included 
as cases from a total of 414 women fulfilling the inclusion crite-
ria. The case definition was death of a fetus after inclusion in the 
MoBa study independent of gestational age before and during 
birt, and live born infants who die up to the end of day 6 after 
birth. Cases with available plasma samples were included. For 
complete inclusion and exclusion criteria see the Supplementary 
material (Table S1). During review of the medical records, 1 case 
was excluded because of incorrect classification, leaving 149 
cases eligible for further analysis. Cases were categorized into 2 
groups: (1) late miscarriage between week 17 and <22 weeks de-
fined as fetal death and/or expulsion before 22 completed weeks 
of gestation (n = 11), and (2) perinatal death group as classified and 
defined in CODAC; born ≥500 g or >22 weeks, stillbirth or death 
after birth until the end of day 6 (n = 138). In the present study, we 
focused on the investigation of the perinatal death group, defined 
above. In this group, the M1 and the M2 biological samples were 
available from 129 and 62 women, respectively, and 46 C samples 
were obtained from the children. To maximize the completeness of 
Conclusions: B19V PCR positivity was high and similar in both cases and controls. In 
our study B19V DNAemia was not seen to be associated with fatal outcome of preg-
nancy. The clinical significance of B19V DNA detection during pregnancy is uncertain. 
Caution is needed when diagnosing a B19V infection based only on B19V DNAemia.
K E Y W O R D S
CODAC, DNAemia, MoBa, parvovirus B19, perinatal death, pregnancy
Key message
High prevalence of B19V-PCR-positive samples in preg-
nant women. Caution is needed when diagnosing a B19V 
infection based only on B19V DNAemia.
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data, the medical hospital records for all cases from 32 different 
hospitals in Norway were reviewed, and relevant data, including 
laboratory data, were combined with the study results. In addition, 
medical records were surveyed to find out if analysis of B19V had 
been performed according to the national guidelines on stillbirth. 
The timing and the reported causes of perinatal death among the 
cases were extracted from medical records and categorized ac-
cording to the CODAC classification system for perinatal death. 
In addition to designating a primary cause of death,23 the system 
also aims to classify associated conditions (AC).19 The cases and 
controls were initially tested for B19V IgG and IgM antibodies by 
an enzyme-linked immunosorbent assay (Institut Virion/Serion 
Gmbh, Würzburg, Germany). Testing for B19V DNA was per-
formed with primers and probes, targeting the VP1 gene of B19V. 
Nucleic acid extraction for B19V was performed on MagNA Pure 
LC (Roche Diagnostics, Basel, Switzerland). Laboratory methods 
have previously been described in detail.24 The analytical sen-
sitivity was at least 500 IU/mL as determined by measurements 
of serial dilutions of the WHO international standard for B19V 
(NIBSC 12/208). Quantification was performed using 2 quantifi-
cation standards made from dilutions of the WHO international 
standard for B19V. High-level viremia was defined as ≥104 IU/mL. 
Low-level viremia was defined as <104 IU/mL. To validate the re-
sults, an alternative B19V PCR assay targeting the VP2 gene was 
used on a selection of positive and negative study samples at an 
external test laboratory at the Department of Microbiology, Oslo 
University Hospital. B19V IgG and IgM antibodies were analyzed 
according to the test algorithm shown in Figure 1. B19V PCR was 
performed in M1, M2 and C samples, if B19V IgG had an equivocal 
result, or if B19V IgM had an equivocal or positive result, and in 
seroconversion samples. A subset of 150 of the 1349 controls was 
randomly selected in an additional comparative B19V PCR study 
with the 129 available M1 samples from the 138 cases. One of the 
150 randomly selected controls had no material left for analysis, 
leaving 149 of the controls eligible for PCR analysis. If available 
material existed, the corresponding M2 and C samples of the B19V 
PCR-positive M1 samples were analyzed.
2.1 | Statistical analyses
The sample size was calculated based on the B19V seroprevalence. A 
sample of 150 cases and 1350 controls was needed to detect an OR 
for B19V infection of 1.5 with a significance level of .05 and power 
of 80%. Seronegative women are at risk of B19V infection in preg-
nancy. The odds of B19V infection for cases and controls were esti-
mated by logistic regression. Odds ratios with accompanying 95% CI 
were used as the measure of relative risk and were calculated both 
with and without adjustment for parity, maternal age, body mass 
index (BMI), and tobacco use in pregnancy. Statistical analyses were 
conducted using IBM SPSS Statistics for Windows, Version 23.0 
(IBM Corp., Armonk, NY). The random selection of 150 M1 control 
samples was done using SPSS.
2.2 | Ethical approval
MoBa has obtained a license from the Norwegian Data Inspectorate 
(01/4325), and a general approval from The Regional Committee for 
Medical Research Ethics (S-97045, S-95113). The current study was 
approved by the Regional Committee for Medical Research Ethics in 
South-Eastern Norway (2012/374B).
3  | RESULTS
Maternal and pregnancy characteristics for cases and controls are 
reported in Table 1. Smoking and BMI above 25 kg/m2 were associ-
ated with perinatal death. The controls were more often seropositive 
(B19V IgG-positive and IgM-negative) (63.1%) than cases (57.4%); 
the OR adjusted for maternal age and parity was 1.27 (95% CI 0.88-
1.83) (Table 2). In 106 of 138 cases, seroconversion was investigated 
by analyzing available plasma samples or previous laboratory results 
collected from medical records. Among cases, 4/41 (9.8%) initially 
seronegative cases seroconverted. Among initially seronegative 
controls, seroconversion occurred in 33/486 (6.8%). Hence the OR 
for seroconversion in cases compared with controls was 1.28 (95% 
CI 0.35-4.70). In the case group, seroconversion occurred in the 
mother of 1 infant who died 1 day after birth in week 26, 1 infant 
with antepartum death in week 33, 1 infant with antepartum death 
in week 36, and 1 infant with intrapartum death in week 40 cat-
egorized in the placenta, congenital anomaly, unknown and placenta 
categories in CODAC, respectively (Table 3).
The B19V PCR results of the M1 samples in cases and the sub-
set of controls that were investigated, showed that B19V-PCR-
positive M1 samples were found in 31/129 (24.0%) cases with 
perinatal death and in 42/149 (28.2%) controls (P = .432). The 
prevalence of positive B19V DNA in available cord blood samples 
showed that mothers with PCR-positive M1 samples transmitted 
B19V vertically to 9.1% of cases and 11.9% of the controls. The 
distribution of the corresponding M2- and C-sample PCR results, 
levels of viremia and distribution in seropositive and seronegative 
samples are shown in Table 4. In both cases and controls, nearly 
half of the PCR-positive samples were seronegative for B19V IgG 
and IgM antibodies in the M1 sample. Among the 4 controls with 
a positive PCR in M2, and a seronegative status in M1, 2 sero-
converted and 2 displayed a high level of viremia indicating de-
layed seroconversion. A complete overview over PCR results and 
serological status are presented in the Supplementary material 
(Table S2).
Using the CODAC classification, 86 (62.3%) perinatal deaths were 
categorized as antepartum, 10 (7.3%) intrapartum, and 41 (29.9%) as 
early neonatal deaths (live-born children who died within the first 
week) according to CODAC, of which the majority 22 (53.7%) died 
within the first 24 hours. One pregnancy (0.7%) was terminated be-
cause of severe maternal preeclampsia and resulted in fetal death.
The causal categories “placental” and “unknown” counted 45 
(32.6%) and 28 (20.3%) cases, respectively, and constituted 53% of 
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all the perinatal death cases (Table 3). Of these, 18 out of 67 (26.9%) 
with an available M1 sample had a positive B19V PCR. The “cord” 
and “unknown” categories had the highest occurrence of a positive 
PCR with 38.5% and 34.6%, respectively. In 65 (47.1%) of the 138 
perinatal death cases, 1 or 2 associated conditions were coded.
According to national guidelines, B19V examination is recom-
mended in all cases of stillbirth. Still, review of medical records 
showed that only 75 (54.3%) had originally been investigated for 
B19V (Table 5). None of the women who seroconverted were origi-
nally verified in the medical records. Only 4 of the 45 cases with “pla-
centa” as main cause of death, had consecutive samples analyzed for 
B19V antibodies and 12 women had no test performed. Among the 
28 cases with unknown cause of death, 5 had no tests performed, and 
only 3 had consecutive samples analyzed for B19V antibodies. Viral 
infection was suspected in 1 of the 149 cases; an antepartum death 
in gestational week 35, with a massive infarction of the placenta and 
histologically suspected viral infection; however, no agent was identi-
fied in the hospital examination. In our analyses, the M1 sample was 
missing, but the woman had a B19V IgG- and IgM-positive result in 
the M2 sample at birth, confirming a recent infection.
4  | DISCUSSION
In the current study, the B19V seroconversion rate is high and it cor-
relates with years of known epidemics in Norway.24 Both maternal 
seronegativity against B19V and seroconversion in pregnancy were 
associated with perinatal death, although the association was not sta-
tistically significant. Our study is limited by a relatively small sample 
of seronegative women for whom we had a maternal plasma sample 
available after birth. We adjusted for maternal age and parity, which 
we regarded as the most relevant confounding factors. We also ad-
justed for maternal prepregnancy BMI and smoking during pregnancy 
as these factors were associated with perinatal death. Our results add 
to the literature, but are not sufficient evidence for a clear association 
between infection with B19V and perinatal death. However, a recent 
meta-analysis found a significant increase in the risk of fetal loss, spon-
taneous abortion and stillbirth after maternal B19V infection in.25
In this nested case-control study, very high numbers of B19V-
DNA-PCR-positive plasma samples were observed at weeks 17-18 of 
gestation both in women with perinatal death and in randomly drawn 
controls, corresponding to 24% and 28%, respectively. The prevalence 
F I G U R E  1   Flowchart of the parvovirus B19 test algorithm in a population-based cohort of pregnant women. Plasma was sampled during 
gestational weeks 17-18 (M1) and at birth (M2) and from the cord blood of newborns (C)
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of positive B19V DNA in available cord blood samples showed that 
mothers with PCR-positive M1 samples transmitted B19V vertically in 
9.1% of cases and in 11.9% of the controls. In our study, B19V DNAemia 
was not seen to be associated with fatal outcome of pregnancy.
Seroprevalence rates in our study are comparable to other stud-
ies among pregnant women.3 It is therefore remarkable that nearly 
half of both cases and controls with a positive PCR in the M1 sample 
were also B19V seronegative and did not express serological signs 
of acute or past infection. For the few samples with a high level of 
viremia, this finding is most likely the result of an acute infection, 
but for the majority with a low level of viremia, an acute infection 
is less likely.
Detectable B19V DNA in tissues and blood without serological 
evidence of past infection is previously described.26,27 Interestingly, 
among the controls, only 2 of the 14 mothers with PCR-positive M2 
samples still had a seronegative status in M2. These 2 control women 
had a high level of viremia, indicating recent infection with delayed 
seroconversion, or captured antibodies in immune complexes not 
detectable in serological assays.14 Antigen persistence after an acute 
infection should normally provoke an antibody response. However, 
altered immune response during pregnancy may be a reason for de-
layed antibody production, which has been described in several case 
reports.11,28
Persistence of B19V at low levels both in immunocompromised 
and immunocompetent individuals after an acute infection is well 
documented. In blood donors, positive B19V DNA samples are usu-
ally observed in <1% of participants.15
Detection of B19V DNA in different tissues has been extensively 
corroborated, even without serological evidence of recent infec-
tion.29,30 High occurrence of B19V DNA was reported in blood sam-
ples from patients with malignancies compared with controls, 50.7% 
vs 4.5%.31 A study among kidney transplant patients showed more 
B19V-PCR-positive cases in the first year after transplantation, cor-
related with the degree of immunosuppression.32 Neither of these 
studies showed a clear association between a positive B19V PCR 
and clinical symptoms of infection. Hence, another possibility is that 
altered immune responses or hormonal changes in pregnancy may 
trigger B19V DNA release from tissues independently of the acute 
Maternal characteristics
Perinatal death 
cases N = 138
Controls 
N = 1349 P-value
Mean age, years 31.0 30.4  
Nulliparous, n (%) 138 (100) 1349 (100)  
Yes 67 647 .895
No 71 702
Missing 0 0  
Smoking in pregnancy, n (%) 114 (82.6) 1193 (81.2)  
Yes 17 97 .014
No 97 1096
Missing 24 156  
Alcohol use in pregnancy, n ( %) 116 (84) 1200 (89)  
Yes 16 161 .910
No 100 1039
Missing 22 149  
Pre-pregnancy body mass index (BMI)
Mean (range)
24.9 (17.5-37.0) 23.7 (16.5-44.8)  
BMI >25 kg/m2, n (%) 137 (99.3) 1324 (98.2)  
Yes 55 409 .027
No 82 915
Missing 1 25  
Having children <6 y, n (%) 62 (45) 715 (53)  
Yes 54 643 .481
No 8 72
Missing 76 634  
Having children attending daycare, n (%) 72 (52.2) 761 (56.4)  
Yes 44 497 .476
No 28 264
Missing 66 588  
Gestational length, weeks, mean (range) 34.5 (22-43) 39.7 (31-44)  
TA B L E  1   Maternal and pregnancy 
characteristics in 138 perinatal death 
cases and 1349 population-based controls 
nested within the Norwegian Mother and 
Child Cohort Study (MoBa)
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infection, resulting in persistence or merely release of naked non-in-
fectious viral DNA.
A recent study showed that detection of B19V DNA in blood was 
not a proof of viral replication and that infectious virions were pres-
ent.33 They showed that after an acute infection with high viremia, 
DNA subsequently became degradable by an endonuclease, indi-
cating detection of no longer encapsidated, but naked, DNA. In our 
study, we found very high numbers of B19V-PCR-positive plasma 
samples in both cases and controls, which may be due to release of 
B19V DNA from sites of persistence in tissues.
Detecting B19V DNA through highly sensitive amplification 
techniques requires careful considerations regarding possibility of 
contamination. We have taken several measures to avoid, and to 
detect, possible contamination and we believe that it can be ruled 
out in the present study.
Moreover, in the current study we demonstrated the value of 
detecting seroconversion to determine maternal infection, under-
scoring the importance of having consecutive samples. In Norway, 
as in several other countries, storage of booking samples in preg-
nancy is not mandatory, and often not available. Through review 
of the medical records we proved that although guidelines recom-
mend it, appropriate testing is lacking in most cases of perinatal 
death.
The classification in CODAC showed that 20% of the perina-
tal deaths were ascribed to the “unknown” cause of death cate-
gory. This is a low estimate compared with most other studies. 
TA B L E  2   Maternal seroprevalence of B19V IgG antibodies at 17-18 wk of gestation, B19V seroconversion and odds ratios with 95% CI 
for perinatal death in cases compared with controls
Maternal characteristics
Perinatal death 



















1.27 (0.88-1.84) 1.27 (0.88-1.83) 1.32 (0.88-1.97)















aAdjusted for maternal age and parity. 
bAdjusted for body mass index, tobacco use in pregnancy, maternal age and parity. 
cSerology results other than B19V seropositive = (IgG+, IgM−), or seronegative = (IgG−, IgM−) in M1 samples are not taken into calculation (129 cases 
and 1318 controls). 
dOnly seronegative = (IgG−, IgM−) in the M1 samples are taken into calculation (41 cases and 486 controls). 
TA B L E  3   Perinatal death cases categorized in the CODAC classification system—cause of death (COD) and associated conditions (AC), 
number of seroconversion samples and B19V-PCR-positive M1 samples displayed in each category
Causes of death (COD) 









0 Infection 9 (6.5) 12.5  Infection 14 15.4
1 Neonatal 8 (5.8) 28.6  Neonatal 12 18.2
2 Intrapartum 7 (5.1) 0  Intrapartum 11 20
3 Congenital anomaly 20 (14.5) 20 1 Congenital anomaly 24 20.8
4 Fetal 5 (3.6) 20  Fetal 9 22.2
5 Cord 13 (9.4) 38.5 1 Cord 30 28.6
6 Placenta 45 (32.6) 22 1 Placenta 65 21.7
7 Maternal 2 (1.5) 0  Maternal 29 29.6
8 Unknown 28 (20.3) 34.6 1 Unknown 28 34.6
9 Termination 1 (0.7) 0  Termination 1 0
Total 138 (100) 24 4    
aM1 samples for B19V PCR analysis were not available in 9 perinatal death cases, 1 case each in COD categories 0, 1 and 2, and 4 cases in category 6 
and 2 cases in category 8. 
bIn 65 of the 138 perinatal death cases, 1 or 2 associated conditions (AC) were coded in addition to COD. 
862  |     BARLINN et AL.
This may be due to a high percentage of autopsy (over 70%) 
and placental investigations (over 70%) among perinatal death 
cases. Both autopsy and placental investigation were performed 
in 57.3% of cases. When including only cases with both autopsy 
and placenta reports, the percentage with placental pathology 
as cause of death increased from 33% to 43%. The case with 
a suspected viral infection, with no causative agent verified at 
the hospital, demonstrates several points; the value of placenta 
histology, the difficulty in obtaining the cause of death, and the 
difficulty in determining whether B19V causes third trimester 
stillbirth.
A strength of this study is that cases and controls were drawn 
among nearly 100 000 pregnant women participating in MoBa, 
a large population-based cohort, over a 10-year time span in-
cluding both endemic and epidemic B19V periods. Cases and 
controls were included independently of symptoms. In contrast 
to studies based on a selection of cases among symptomatic 
women with acute infection, this study gives valuable insight 
for a clinical setting. It evaluates the potential effect of screen-
ing for B19V infection in perinatal death, and the pitfalls that 
may arise because the combination of serology and PCR anal-
ysis are recommended when investigating B19V infections in 
pregnancy.12-14,28,34
5  | CONCLUSION
The current study has practical implications for diagnosing B19V infec-
tion during pregnancy and investigation of the role of B19V as a cause 
of perinatal death. High prevalence of B19V-PCR-positive samples was 
detected both in cases and controls. The clinical significance of B19V 
DNA detection in blood is uncertain and warrants caution in diagnos-
ing a B19V infection during pregnancy or when screening for cause of 
perinatal death, based on detecting DNAemia only.
TA B L E  4   Number of M1-B19V-PCR-positive samples among perinatal death cases (N = 31) and controls (N = 42), and the corresponding 
M2 and C sample PCR results, levels of viremia and distribution in seropositive and seronegative samples
Sample
M1 M1 M2a Cb
B19V-DNA PCR+ High-level viremia B19V-DNA PCR+ B19V DNA PCR+
Perinatal death
Seropositive in M1 17 2 2c 1
Seronegative in M1 14 2d 0 0
Total B19V PCR+ (%) 31/129 (24%) 4 2/18 1/11 (9.1%)
Controls
Seropositive in M1 24 2 10e 1f
Seronegative in M1 18 2 4g 4h
Total B19V PCR+ (%) 42/149 (28.2%) 4 14/42 5/42 (11.9%)
Note: Seronegative: IgG and IgM negative for B19V antibodies in M1. Seropositive: IgG positive and IgM negative for B19V antibodies in M1. High-
level viremia, ≥104 IU/mL, low-level viremia, <104 IU/mL.
aMissing 13 of 31 M2 samples from perinatal death cases. 
bMissing 20 of 31 C samples from perinatal death cases. 
cOne sample had a high level of viremia, with significant rise in IgG and equivocal IgM result. The corresponding C sample was 
B19V-DNA-PCR-positive. 
dBoth missing sample in M2. 
eThree samples with high level of viremia, of which 1 was also IgM positive. 
fThe mother had IgG- and IgM-positive result in M1 and IgG-positive and IgM-equivocal result in M2. 
gAll 4 had a high level of viremia, 2 had a seroconversion and 2 were still seronegative in M2. 
hTwo mothers had a seroconversion and 2 were still seronegative in M2. 
TA B L E  5   Investigation type in 138 perinatal death cases
Type of investigation 
after adverse outcome Placenta N (%) Autopsy N (%)
Placenta and 
autopsy N (%)
B19V serology performed N (%)
None




 99 (71.7) 99 (71.7) 79 (57.3) 63 (46) 62 13
Abbreviations: N, number; placenta, placenta histology report.
aTwo women exclusively for IgG and 6 women exclusively for IgM. 
bOf which 5 only had IgG tests performed. 
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Increased knowledge of the immune responses in pregnancy, 
the impact on serological diagnosis, and development of methods 
able to differentiate between replicating virus and virus DNA are 
needed.
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